- NIH Collaboratory

Health Care Systems Research Collaboratory

Rethinking Clinical Trials®

What are ePCTs?

Catherine M. Meyers, MD Director, Office of Clinical & Regulatory Affairs National Center for Complementary and Integrative Health (NCCIH)

Essentials of Embedded Pragmatic Clinical Trials Seminar



- Identify key considerations in the design and conduct of ePCTs and how they differ from explanatory trials
- Learn about the advantages and disadvantages of ePCTs, and when a pragmatic approach can be used to answer the research question
- Provide an understanding of the PRECIS-2 tool and its ability to assist teams in the design of an ePCT

↔ Important things to know

- ePCTs are designed to answer important, realworld clinical questions
- Broad stakeholder engagement and support are essential from beginning to end
- Tradeoffs in flexibility, adherence, and generalizability are inevitable

ePCT characteristics

- Conducted within healthcare systems
- Use streamlined procedures and existing infrastructure
- Answer important medical questions



Why conduct ePCTs?



ePCTs have the potential to inform policy and practice with high-quality evidence at reduced cost and increased efficiency compared with traditional clinical trials

ePCTs bridge clinical care and research

Study designed with input from health system stakeholders

Data collected through EHR in health care settings

Outcomes important to decision makers

Intervention incorporated into routine clinical workflow

Diverse, representative study populations

Key differences between explanatory and pragmatic trials

	EXPLANATORY	PRAGMATIC
Research question	Efficacy: Can the intervention work under the best conditions?	Effectiveness: Does the intervention work in routine practice?
Setting	Well-resourced "ideal" setting	Routine care settings including primary care, community clinics, hospitals
Participants	Highly selected	More representative with less strict eligibility criteria
Intervention design	Tests against placebo, enforcing strict protocols & adherence	Tests 2 or more real-world treatments using flexible protocols, as would be used in routine practice
Outcomes	Often short-term surrogates or process measures; data collected outside of routine care	Clinically important endpoints; at least some data collected in routine care
Relevance to practice	Indirect: Not usually designed for making decisions in real-world settings	Direct: Purposefully designed for making decisions in real-world settings

Adapted from Zwarenstein M, Treweek S, Gagnier JJ, et al. BMJ. 2008;337:a2390. doi: 10.1136/bmj.a2390. PMID: 19001484

Common-sense definition

Designed for the primary purpose of informing decision-makers regarding the comparative balance of benefits, burdens and risks of a biomedical or behavioral health intervention at the individual or population level.

Califf RM, Sugarman J. Clin Trials. 2015 Oct;12(5):436-41. doi: 10.1177/1740774515598334

Balancing relevance and efficiency




- Achieving both relevance and efficiency is a goal of pragmatic trials, yet high relevance to real-world decision-making may come at the expense of trial efficiency
- For example, a trial measuring outcomes that matter most to patients and health systems may not be able to rely exclusively on information from the EHR, and instead need to assess patientreported outcomes, which is more expensive and less efficient

Resource: What are ePCTs?

Why Are We Talking About Pragmatic Clinical Trials?


From the Living Textbook of Pragmatic Clinical Trials www.rethinkingclinicaltrials.org



Introducing PRECIS-2

Pragmatic–Explanatory Continuum Indicator Summary (PRECIS) tool

PRECIS-2 can be a useful tool for understanding variability in pragmatic trial characteristics



PRECIS-2: Kirsty Loudon et al. BMJ 2015;350:bmj.h2147. Copyright 2015 by British Medical Journal Publishing Group. Used by permission.



PRECIS-2: Designing trials fit for purpose

Tool assesses trial across 9 domains

Explanatory

Pragmatic

- 1. Eligibility
- 2. Recruitment
- 3. Setting
- 4. Organization
- 5. Flexibility: delivery
- 6. Flexibility: adherence
- 7. Follow-up
- 8. Primary outcomes
- 9. Primary analysis



Who is selected to participate in the trial?

Explanatory

Pragmatic

Highly selected patients, strict inclusion criteria Typical patients, minimal inclusion criteria



How are participants recruited into the trial?

Explanatory

Pragmatic

Uses methods and resources outside of, or in addition to, what is typical Recruited in usual healthcare settings; participants may include patients, providers, or health systems



Where is the trial being done?

Explanatory

Pragmatic

Specialist practice or academic medial center

Settings where the trial's results will be applied



What expertise and resources are needed to deliver the intervention?

Explanatory

Pragmatic

Changes the workflow, adds equipment or staff training, or affects how care is typically delivered Changes to clinical delivery and resources are minimal, easy to implement in usual care after the trial



How should the intervention be delivered?

Explanatory

Pragmatic

Highly specified, protocol-driven with timing of intervention tightly defined Details of intervention delivery left to the care provider



PRECIS-2: Flexibility-adherence

What measures are in place to ensure participants adhere to the intervention?

Explanatory

Pragmatic

Measures to monitor patient adherence and excludes patients judged not to be adherent No special measures to enforce intervention engagement or compliance



How closely are participants followed up?

Explanatory

Pragmatic

Frequent follow-up visits scheduled outside of clinical encounters, extensive data collection Few follow-up visits, outcome data obtained through EHR, questionnaires, or other data sources



How relevant is it to participants?

Explanatory

Pragmatic

Surrogate outcomes or measures distinct from the research question Outcomes of importance to patients, measured as they would be in usual care



To what extent are all data included?




Pragmatic

Excludes noncompliant participants, dropouts, or practice variability

Intent-to-treat analysis

Sample PRECIS-2 wheels




- --- Planning phase
- Implementation phase

Resource: Using PRECIS-2

Pragmatic Elements: An Introduction to PRECIS-2

From the Living Textbook of Pragmatic Clinical Trials www.rethinkingclinicaltrials.org



Important things to do

- For each domain of PRECIS-2, determine the approach along the pragmaticexplanatory continuum that is most appropriate for answering your research question
- Remember that trials may have some elements that are more pragmatic and some that are more explanatory